Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Debbie G J, Robbrecht"'
Autor:
Chantal F. Stockem, Sarah M. H. Einerhand, Isabel Miras Rodríguez, Youssra Salhi, Esther Pérez, Dimitra R. Bakaloudi, Rafee Talukder, Belen Caramelo, Rafael Morales-Barrera, Astrid De Meulenaere, Alessandro Rametta, Andrea Bottelli, Felix Lefort, Patrizia Giannatempo, Christof Vulsteke, Joan Carles, Ignacio Duran, Petros Grivas, Alfonso Gómez de Liaño, Debbie G. J. Robbrecht, Begoña P. Valderrama, Vincent van der Noort, Michiel S. van der Heijden
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background Anti-PD-(L)1 agent are approved as first- and second-line treatment options in advanced urothelial cancer (UC), but information about long-term survival is scarce. There is a need for prognostic factors, as these may help in the d
Externí odkaz:
https://doaj.org/article/567d40a068b9449d86c2a2294518a0e0
Autor:
Maud Rijnders, J. Alberto Nakauma-González, Debbie G. J. Robbrecht, Alberto Gil-Jimenez, Hayri E. Balcioglu, Astrid A. M. Oostvogels, Maureen J. B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J. L. H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets, Martijn P. Lolkema
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of response, b
Externí odkaz:
https://doaj.org/article/5c826962a5fb45ffbb47fc08f0218098
Autor:
Pauline A. J. Mendelaar, Debbie G. J. Robbrecht, Maud Rijnders, Ronald deWit, Vanja deWeerd, Teoman Deger, Hans M. Westgeest, Maureen J. B. Aarts, Jens Voortman, John W. M. Martens, Astrid A. M. van derVeldt, José Alberto Nakauma‐González, Saskia M. Wilting, Martijn Lolkema
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 2086-2097 (2022)
Second‐line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour‐derived DNA (ctDNA) levels may guide patient stratification, provided that an affordabl
Externí odkaz:
https://doaj.org/article/697816219cc74830a6f744569b38649b
Autor:
Marit A. C. Vermunt, Debbie G. J. Robbrecht, Lot A. Devriese, Julie M. Janssen, Bas Thijssen, Marianne Keessen, Maarten vanEijk, Rob Kessels, Ferry A. L. M. Eskens, Jos H. Beijnen, Niven Mehra, Andries M. Bergman
Publikováno v:
Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)
Abstract Background ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase
Externí odkaz:
https://doaj.org/article/ad84cb565b37425dadb093bae9e81fac
Autor:
Maaike E. A. van Sasse van IJsselt, Diane A. J. van der Biessen, Andrea J. van Puffelen, Debbie G. J. Robbrecht, Wendy H. Oldenmenger
Publikováno v:
Supportive Care in Cancer, 31(5):290. Springer-Verlag
Abstract Purpose Until today, it is not clear why patients decide to continue with early clinical trial (ECT) participation. Therefore, the aim of this study is to explore to which extent the self-determination theory of Ryan and Deci, according to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::825ca7eddf478d5b9967d76ec350195b
https://doi.org/10.21203/rs.3.rs-2370427/v1
https://doi.org/10.21203/rs.3.rs-2370427/v1
Autor:
Maud Rijnders, Debbie G. J. Robbrecht, Astrid A. M. Oostvogels, Mandy van Brakel, Joost L. Boormans, Maureen J. B. Aarts, Hayri E. Balcioglu, Paul Hamberg, Jens Voortman, Hans M. Westgeest, Martijn P. Lolkema, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets
Publikováno v:
Cancer Immunology and Immunotherapy. Springer Science and Business Media Deutschland GmbH
Rijnders, M, Robbrecht, D G J, Oostvogels, A A M, van Brakel, M, Boormans, J L, Aarts, M J B, Balcioglu, H E, Hamberg, P, Voortman, J, Westgeest, H M, Lolkema, M P, de Wit, R, van der Veldt, A A M & Debets, R 2022, ' A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer ', Cancer Immunology and Immunotherapy . https://doi.org/10.1007/s00262-022-03250-0
Cancer Immunology Immunotherapy, 72(3), 759-767. Springer Science+Business Media
Cancer Immunology Immunotherapy, 72(3), 759-767. Springer
Cancer Immunology, Immunotherapy. Springer Science and Business Media Deutschland GmbH
Rijnders, M, Robbrecht, D G J, Oostvogels, A A M, van Brakel, M, Boormans, J L, Aarts, M J B, Balcioglu, H E, Hamberg, P, Voortman, J, Westgeest, H M, Lolkema, M P, de Wit, R, van der Veldt, A A M & Debets, R 2022, ' A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer ', Cancer Immunology and Immunotherapy . https://doi.org/10.1007/s00262-022-03250-0
Cancer Immunology Immunotherapy, 72(3), 759-767. Springer Science+Business Media
Cancer Immunology Immunotherapy, 72(3), 759-767. Springer
Cancer Immunology, Immunotherapy. Springer Science and Business Media Deutschland GmbH
PD1 inhibition is effective in patients with metastatic urothelial cancer (mUC), yet a large fraction of patients does not respond. In this study, we aimed to identify a blood-based immune marker associated with non-response to facilitate patient sel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7784bbc991c93287040abd2711743142
https://research.vumc.nl/en/publications/8a26f362-1a9c-4951-8b87-ccc8f09f24d4
https://research.vumc.nl/en/publications/8a26f362-1a9c-4951-8b87-ccc8f09f24d4
Autor:
Debbie G J, Robbrecht, Fazil, Alidjan, Bob, Eikemans, Dirk A W, Haans, Coen, van Guldener, Peter, van Wijngaarden
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 155(25)
Mesenteric panniculitis is a non-specific inflammation of the mesenteric adipose tissue, with varying degrees of fibrosis and fat necrosis. It can be associated with varying diseases and conditions, such as autoimmune disease and cancer. Many doctors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::74c5f092342d1d8f41a8eac10014de27
https://pubmed.ncbi.nlm.nih.gov/22748362
https://pubmed.ncbi.nlm.nih.gov/22748362